VIP (Vasoactive Intestinal Peptide)

Common side effects:

• Transient facial flushing or redness due to vasodilation.
• Mild to moderate headaches following administration.
• Gastrointestinal disturbances including diarrhea or nausea.
• Temporary drops in blood pressure (hypotension).
• Increased heart rate (tachycardia) as a compensatory response.

Rare or serious side effects:

• Severe hypotensive episodes requiring medical intervention.
• Exacerbation of certain neuroendocrine tumor symptoms.
• Significant alterations in cranial hemodynamics leading to severe migraines.
• Allergic reactions or hypersensitivity to synthetic analogs.

Receptor Activation and cAMP Signaling drive the primary cellular effects of the VIP (Vasoactive Intestinal Peptide) peptide. Upon administration, VIP binds to specific G-protein-coupled receptors, primarily VPAC1 and VPAC2, which are widely distributed across immune cells, neurons, and smooth muscle tissues (Gourlet et al., 1998). This binding stimulates adenylate cyclase activity, leading to a rapid intracellular accumulation of cyclic AMP (cAMP) and subsequent activation of protein kinase A (PKA).

Immune Modulation and Vasodilation occur as downstream results of this signaling cascade. In the immune system, elevated cAMP inhibits the production of pro-inflammatory cytokines like TNF-alpha while upregulating anti-inflammatory mediators. Simultaneously, in vascular and respiratory smooth muscle, the PKA pathway reduces intracellular calcium levels, causing potent relaxation, vasodilation, and bronchodilation.

Discovery and Isolation of VIP occurred in 1970 when researchers first extracted the 28-amino acid peptide from porcine intestines. Initially recognized purely for its profound vasodilatory effects on the gut, subsequent mapping revealed its extensive presence throughout the central and peripheral nervous systems. This reclassified VIP from a localized gut hormone to a ubiquitous neuropeptide crucial for neuroendocrine and immune communication.

Clinical Development and Regulatory Status have evolved significantly as researchers explore VIP analogs for complex diseases. While natural VIP has a very short half-life, synthetic long-acting analogs like Aviptadil and PB1046 have entered multiple clinical trials for conditions ranging from pulmonary arterial hypertension to severe COVID-19-induced ARDS (Phase 3 ACTIV-3b Trial). Currently, VIP remains primarily a research-only compound, though specific formulations have received orphan drug designations for targeted cardiopulmonary indications.